Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient, marking a significant advancement in its antifungal drug portfolio [1] Group 1 - The drug Sulfate Isavuconazole is a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - The registration application for this drug was submitted to the National Medical Products Administration in April 2024 and has been accepted [1]

新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内 ESG 生态体系的加速完善，政策监管持续收紧、资本市场对 ESG 表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的 重要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建 18套行业ESG评价模型，纳入150余项 ESG 指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国 ESG 实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 上海医药在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，上海医药成功入选本 次 ...

Major Events - CATL (03750) plans to issue an additional 34.8584 million shares [1] - MINIMAX-WP (00100) fully exercised its over-allotment option involving a total of 4.3796 million shares [1] - MIRXES-B (02629) established a strategic partnership with N Health, and its HELICORapid and FITRapid home testing kits received regulatory approval [1] - LFG Investment Holdings (03938) was acquired by Chen Shaoyang, who purchased approximately 61.43% of shares at a discount of about 59.46% through a cash offer, with resumption of trading on January 12 [1] - Xiansheng Pharmaceutical (02096) plans to spin off its H-shares for independent listing on the main board of the Hong Kong Stock Exchange [1] - OmniVision Technologies (00501) saw its public offering in Hong Kong oversubscribed by 9.28 times, with a share price of HKD 104.8 [1] - China Nonferrous Mining (01258) released its production guidance for 2026, expecting a total copper output of approximately 484,000 tons [1] - China Rare Earth Holdings (03788) reported a 53.1% increase in JORC ore reserves to 2.62 million ounces, with JORC gold resources rising to 5.54 million ounces [1] - Black Sesame Intelligence (02533) plans to issue a total of 30.1319 million subscription shares, raising approximately HKD 568 million [1] - Shanghai Pharmaceuticals (02607) received approval for the production of bromhexine oral solution [1] - Beijing Energy International (00686) signed an EPC contract for a 100 MW wind power project in Heilongjiang Province [1] - Standard Chartered Group (02888) plans to issue SGD 750 million fixed-rate reset perpetual subordinated convertible securities [1] Share Buybacks/Reductions - Geely Automobile (00175) repurchased 1.547 million shares for HKD 26.6229 million on January 9 [2] - Sunny Optical Technology (02382) repurchased 840,000 shares for HKD 53.9894 million on January 9 [2] - Xiaomi Group-W (01810) repurchased 4 million shares for HKD 151 million on January 9 [2] Operating Performance - China Jinmao (00817) achieved a cumulative contracted sales amount of RMB 113.5 billion for 2025, a year-on-year increase of 15.52% [2] - Jiumaojiu (09922) reported stable performance for its main brands in the fourth quarter [2] - CIFI Holdings Group (00884) recorded a cumulative contract sales amount of approximately RMB 16.1 billion for 2025 [2] - R&F Properties (02777) reported total sales revenue of approximately RMB 14.21 billion for 2025, a year-on-year increase of 26.54% [2] - Zhongliang Holdings (02772) reported a cumulative contract sales amount of approximately RMB 12.07 billion for 2025, a year-on-year decrease of 32.68% [2] - Shui On Land (00272) achieved a cumulative contract property sales amount of RMB 7.916 billion for 2025 [2] Additional Performance Metrics - Greenland Hong Kong (00337) reported contract sales of approximately RMB 7.214 billion for 2025, a year-on-year decrease of 21.66% [3] - Yuzhou Group (01628) achieved a cumulative sales amount of RMB 6.727 billion for 2025 [3] - New World Development (01030) reported contract sales of approximately RMB 1.354 billion in December [3] - China Shipbuilding Defense (00317) expects a year-on-year increase of 149.61% to 196.88% in net profit attributable to shareholders for 2025 [3] - Longyuan Power (00916) completed a cumulative power generation of 76.4694 million MWh for 2025, a year-on-year increase of 1.22% [3] - Sunny Optical Technology (02382) reported a December shipment of 95.592 million mobile phone lenses, a year-on-year decrease of 8.9% [3] - COFCO Joycome (01610) reported a December pig output of 567,000 heads, a month-on-month increase of 1.43% [3] - Dekang Agriculture (02419) sold 1.1097 million pigs in December, generating sales revenue of RMB 1.664 billion [3] - Hengding Industrial (01393) reported a coal output of 5.415 million tons for 2025, a year-on-year increase of 31% [3] - Orient Overseas International (00316) reported a 17.2% decrease in quarterly shipping revenue compared to the same period last year, with total cargo volume up 0.8% and carrying capacity up 4.5% [3]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of Pyridostigmine oral solution, which is used to treat myasthenia gravis [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Bromides of Pyridostigmine oral solution [1] - The drug was first launched in the United States in 1965, indicating a long history of use in the treatment of myasthenia gravis [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the oral solution, which is used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The oral solution of Bromides has been granted a drug registration certificate (Certificate No: 2025S04074) by the National Medical Products Administration [1] - The product was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - Shanghai Pharmaceuticals submitted the registration application for this product in April 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 2.3174 million in research and development for this product as of the date of the announcement [1] - There are currently no other companies in China that have this product listed for sale [1] Group 3: Market Potential - According to the IQVIA database, the procurement amount for Bromides tablets in hospitals in mainland China is RMB 60.29 million for the year 2024 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of bromhexine oral solution, indicating a significant advancement in its product portfolio [1] Group 1 - Shanghai Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd., has obtained a drug registration certificate for bromhexine oral solution [1] - The drug registration certificate number is 2025S04074, confirming the approval for production [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於溴吡斯的明口服溶液獲得批准生產的公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 10 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 证券代码：601607 证券简称：上 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for its oral solution of Pyridostigmine Bromide, which is approved for production [1] Group 1 - The oral solution of Pyridostigmine Bromide is used for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1965 [1] - Shanghai Shiyou submitted the registration application for this drug to the National Medical Products Administration in April 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 2.3174 million in research and development for this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

Group 1 - The core point of the article is that Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the Ming oral solution, which is used to treat myasthenia gravis [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - As of the announcement date, the company has invested approximately 2.3174 million yuan in the research and development of this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

关于溴吡斯的明口服溶液获得批准生产的公告 上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 编号：临 2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海上药中西 制药有限公司（以下简称"上药中西"）的溴吡斯的明口服溶液（以下简称"该 药品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注 册证书》（证书编号：2025S04074），该药品获得批准生产。 一、该药品基本情况 药品名称：溴吡斯的明口服溶液 剂型：口服溶液剂 规格：473ml：5.676g 注册分类：化学药品 3 类 药品批准文号：国药准字 H20256499 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 截至本公告日，中国境内该药品暂无其他企业上市。 IQVIA 数据库显示，2024 年中国大陆医院采购溴吡斯的明片剂金额为人民 币 6,029 万元。 1 三、对上市公司影响及 ...